RG

Ritik Gupta

Active Director Director DIN 10433160
DIN 10433160 First appointment Dec 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2023
Shareholding value •••• Premium profile

About Ritik Gupta

Data last updated:

Ritik Gupta is a Director at Meulyf Pharmaceuticals Private Limited (since 2023). The company operates in Pharma. Meulyf Pharmaceuticals Private Limited reported revenue of ₹84,552 (FY 2025).

DIN 10433160
Primary Designation Director
Industry Pharma
First Appointment 20 Dec 2023
Oldest Company Age 2 yrs
Largest company Meulyf Pharmaceuticals Private Limited · ₹84,552 (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director20 Dec 20232023₹84,552 (FY 2025)Active

Board colleagues of Ritik Gupta

NameDINCompanyDesignation
Tushar Sharma10433159Meulyf Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Meulyf Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Ritik Gupta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ritik Gupta

Ritik Gupta currently holds 1 directorship: Meulyf Pharmaceuticals Private Limited (Director, since 20 Dec 2023, revenue ₹84,552 (FY 2025)).

Ritik Gupta was first appointed on 20 Dec 2023 as Director at Meulyf Pharmaceuticals Private Limited.

The current boards of Ritik Gupta's companies include Tushar Sharma (Meulyf Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available